| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap |
NCT03861936: BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence |
|
|
| Completed | 2b | 150 | US | OnabotulinumtoxinA, BOTOX®, botulinum toxin Type A, Normal saline | Allergan | Masseter Muscle Prominence | 04/20 | 07/20 | | |
ACTRN12614000196640: Evaluation of the efficacy of intradermal onabotulinumtoxinA for the treatment of accordion (cheek) wrinkles: A 2-centre randomized double-blinded split face clinical trial |
|
|
| Recruiting | 2 | 20 | | | David Ellis, Investigator-initiated trial grant from Allergan Inc. | Presence of accordion (cheek) wrinkles | | | | |
| Completed | 2 | 40 | US | Botulinum toxin type A | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Cerebral Palsy, Muscle Spasticity | 06/02 | | | |
NCT00651729: Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity |
|
|
| Completed | 2 | 279 | US, Canada | Botulinum Toxin Type A, BOTOX® | Allergan | Stroke, Muscle Spasticity | 12/04 | 12/04 | | |
NCT00651690: Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment |
|
|
| Completed | 2 | 62 | US | Botulinum Toxin Type A, BOTOX®, Placebo | Allergan | Stroke, Muscle Spasticity | 05/05 | 05/05 | | |
2005-005252-40: A Prospective Evaluation of BOTOX® and Dysport® in Temporal Brow Elevation |
|
|
| Completed | 2 | 40 | Europe | BOTOX®, Dysport®, n/a, N/A, Powder for solution for injection, Injection*, BOTOX®, Dysport® | Aalst Dermatology Group | For subjects who desire brow lift as a means to rejuvenate the upper face. | | | | |
2005-005254-41: An Open-Label, Crossover Evaluation of the Safety and Patient Satisfaction of Dysport® Compared With BOTOX® in Subjects That Previously Received BOTOX® Treatment for Moderate to Severe Upper Facial Rhytids |
|
|
| Completed | 2 | 40 | Europe | Dysport®, N/A, Injection*, Dysport® | Aalst Dermatology Group | Upper face rhytids | | | | |
2005-005235-96: A Double-Blind Comparison of the Safety and Efficacy of Dysport® and BOTOX® (Botulinum Toxin Type A) in the Treatment of Female Subjects with Severe Glabellar Rhytids |
|
|
| Completed | 2 | 60 | Europe | BOTOX®, Dysport®, N/A, Powder for solution for injection, Injection*, BOTOX®, Dysport® | Cranley Clinic | Severe glabellar rhytids | | | | |
NCT00467207: Intensive Strength Training in Children With Cerebral Palsy - Effect on Hand Function |
|
|
| Completed | 2 | 10 | Europe | Botulinum Toxin A, Botox, BoNT A, Resistance training, Strength training | St. Olavs Hospital, Norwegian University of Science and Technology | Cerebral Palsy | 10/07 | 03/08 | | |
| Completed | 2 | 313 | US, Canada, Europe | botulinum toxin Type A, BOTOX®, Placebo | Allergan | Overactive Bladder, Urinary Incontinence | 01/08 | 06/08 | | |
| Completed | 2 | 242 | US, Canada, Europe, RoW | botulinum toxin type A, BOTOX®, botulinum toxin type A Formulation 2, Normal Saline | Allergan | Cervical Dystonia | 12/08 | 12/09 | | |
NCT00765375: Safety and Efficacy of the Use of Botox on Acne |
|
|
| Terminated | 2 | 5 | US | Botulinum Neurotoxin Type A, Botox, Bacteriostatic saline | DeNova Research | Acne Vulgaris | 12/08 | 12/08 | | |
NCT00403273: Safety and Efficacy of Botulinum Toxin A Injection in Patients With Painful Artificial Knee Arthroplasty (TKA) |
|
|
| Completed | 2 | 54 | US | Botulinum toxin A, Botox, Normal Saline, saline control | Minneapolis Veterans Affairs Medical Center, University of Minnesota, Arthritis Foundation | Knee Pain | 01/09 | 01/09 | | |
NCT00284518: Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia |
|
|
| Completed | 2 | 380 | Canada, Europe, RoW | botulinum toxin Type A, BOTOX®, normal saline | Allergan | Benign Prostatic Hyperplasia | 05/09 | 05/10 | | |
| Completed | 2 | 134 | US | botulinum toxin type A (BoNT/A), marketed in the US as BOTOX by Allergan | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), George Washington University | Benign Prostatic Hyperplasia | 06/09 | 12/09 | | |
NCT00076687: Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function |
|
|
| Completed | 2 | 155 | US, Europe | botulinum toxin Type A, BOTOX®, saline | Allergan | Stroke, Muscle Spasticity, Motor Neuron Disease | 08/09 | 08/09 | | |
NCT00175669: Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking |
|
|
| Completed | 2 | 32 | Canada | Botox injections | University of British Columbia | Idiopathic Toe Walking | 11/09 | 11/09 | | |
NCT00711087: Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344) |
|
|
| Terminated | 2 | 1 | US | BOTOX-A, BTX-A, Botulinum Toxin Type A, Saline injection | Baylor College of Medicine, U.S. Department of Education | Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury | 02/10 | 02/10 | | |
| Terminated | 2 | 74 | Europe, RoW | Normal saline (Placebo); botulinum toxin Type A (200U), BOTOX®, botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U), botulinum toxin Type A (200U) | Allergan | Overactive Bladder | 02/10 | 07/10 | | |
NCT00231491: Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. |
|
|
| Completed | 2 | 160 | Europe | Botulinum Toxin A (Botox ) | Assistance Publique - Hôpitaux de Paris | Overactive Bladder | 04/10 | 04/10 | | |
| Completed | 2 | 30 | Europe | Botulinum Toxin Type A - Azzalure, Botulinum Toxin Type A - Vistabel | Galderma R&D | Wrinkles | 04/10 | 05/10 | | |
2005-004281-17: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic Hyperplasia |
|
|
| Completed | 2 | 350 | Europe, RoW | BOTOX®, 9060X, Powder for solution for injection, BOTOX® | Allergan Inc., ALLERGAN | Patients with lower urinary tract symptoms due to Benign Prostatic Hyperplasia, Diseases [C] - Male diseases of the urinary and reproductive systems [C12] | | 05/10 | | |
| Completed | 2 | 30 | Europe | clostridium botulinum toxin type A neurotoxin complex, Vistabel, Botox Cosmetic, Botox, 0.9% NaCl solution, NaCl 0.9% B. Braun | University Hospital, Basel, Switzerland, Hannover Medical School | Depression | 10/10 | 10/10 | | |
NCT00444886: Treatment of Thoracic Outlet Syndrome (TOS) With Botox |
|
|
| Completed | 2 | 40 | Canada | Botulinum Toxin Type A injection (BOTOX) | University of British Columbia, Allergan | Thoracic Outlet Syndrome | 02/11 | 02/11 | | |
NCT01107392 / 2010-020172-30: Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia |
|
|
| Completed | 2 | 315 | Canada, US, Europe, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA, Normal saline | Allergan | Benign Prostatic Hyperplasia | 03/12 | 06/12 | | |
NCT00681148: Botulinum Toxin Injection With Prostate Brachytherapy |
|
|
| Withdrawn | 2 | 0 | US | Botox injection, Botox, Saline injection, NS | Emory University | Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation | 07/12 | 07/12 | | |
Impartox, NCT01331356: Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia |
|
|
| Completed | 2 | 18 | Europe | Botox | Nantes University Hospital | Proctalgia | 07/12 | 07/12 | | |
2008-004858-33: Open label pilot study to treat women with chronic urinary retention or voiding dysfunction due to a primary disorder of sphincter relaxation (Fowler’s syndrome) with outpatient urethral sphincter injections of botulinum toxin A (BoNT-A) |
|
|
| Completed | 2 | 10 | Europe | Botox®, NA, Powder for solution for injection | University College London | Primary abnormality of the urethral sphincter or Fowlers Syndrome | | | | |
NCT01485601: Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines |
|
|
| Completed | 2 | 121 | RoW | MT10109 | Medy-Tox | Glabellar Frown Lines | 03/12 | 08/12 | | |
NCT01282541: Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora |
|
|
| Completed | 2 | 26 | US | Botulinum Toxin Type A, Botox | Merbs, Shannath, M.D., Ph.D. | Epiphora | 09/12 | 09/12 | | |
NCT01564979: Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm |
|
|
| Unknown status | 2 | 26 | RoW | preseptal injection of botulinum toxin type A, Botox, pretarsal injection of Botulinum toxin type A | Khon Kaen University | Hemifacial Spasm | 09/12 | 12/12 | | |
NCT01392963: The Treatment of Depression With Botulinum Type A Toxin |
|
|
| Completed | 2 | 30 | US | botulinum toxin type A neurotoxin complex, Botox, botulinum toxin type A (BTA), Placebo, botulinum toxin type A neurotoxin complex matched injection | Seton Healthcare Family | Depression | 11/12 | 06/13 | | |
2012-003479-20: Study of treatment of tennis elbow with Botox. Undersökning av behandling av tennisarmbåge med Botox |
|
|
| Ongoing | 2 | 50 | Europe | botulinum toxin, Powder for solution for injection, Dysport | Handkirurgiska kliniken, Universitetssjukhuset Örebro, Handkirurgiska kliniken, Universitetssjukhuset Örebro | Chronic lateral humerus epiconcylitis Kronisk lateral humerusepikondylit., Tennis elbow Tennisarmbåge., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT01588574: Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia |
|
|
| Completed | 2 | 60 | RoW | MT10109, BOTOX(Registered trade mark) | Medy-Tox | Cervical Dystonia | 10/13 | 12/13 | | |
NCT01682603: Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients |
|
|
| Completed | 2 | 34 | RoW | Botulinum toxin A, BoNT-A (BOTOX 300U) | Buddhist Tzu Chi General Hospital | Spinal Cord Injuries | 12/13 | 12/13 | | |
NCT02907268: Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study |
|
|
| Completed | 2 | 10 | NA | onabotulinumtoxinA, Botox, abobotulinumtoxinA, Dysport | ICLS Dermatology & Plastic Surgery | Facial Rhytids | 01/14 | 01/14 | | |
| Completed | 2 | 18 | Europe | Botox injection, Placebo injection | Hospices Civils de Lyon | Sialorrhea, Amyotrophic Lateral Sclerosis | 03/14 | 03/14 | | |
| Completed | 2 | 120 | Europe | onabotulinumtoxinA, Botox, Botulinum toxin type-A, Placebo | Sandwell & West Birmingham Hospitals NHS Trust, Keele University, Stroke Research Network | Stroke, Muscle Spasticity, Contracture | 05/14 | 05/14 | | |
NCT01657409: Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome |
|
|
| Completed | 2 | 90 | RoW | BoNT-A (10 injection), Botulinum Toxin A (Botox), BoNT-A (20 injection), BoNT-A (40 injection) | Buddhist Tzu Chi General Hospital | Overactive Bladder | 06/14 | 06/14 | | |
2012-005344-15: The Effect of Botox Applied in TC-3 Gel in Patients Suffering From Overactive Bladder. |
|
|
| Completed | 2 | 48 | RoW | Powder for solution for injection, BOTOX botulini toxinum typus A (prášek pro přípravu injekčního roztoku, 100 jednotek v 1 lahvičce - powder for solution for injection, 100 units in 1 vial) | Adyton, s.r.o., Adyton, s.r.o. | Overactive bladder (OAB) syndrome (in women), as defined by the International Continence Society (ICS): severe urgency with or without urge urinary incontinence, usually accompanied with increased daytime frequency and nocturia, in the absence of urinary tract infection or other obvious patology. Syndrom hyperaktivního měchýře (bez přítomnosti infekce nebo jiné zjevné patologie močového ústrojí), se symptomy imperativního a/nebo častého nucení na močení, případně urgentní inkontinence a nykturie., Overactive bladder syndrome with symptoms of an urgent feeling to go to the toilet, going to the toilet frequently, and sometimes leaking urine before getting to the toilet (urge incontinence). Hyperaktivní močový měchýř, s projevy náhlé a nutkavé potřeby močit, časté frekvence močení, případně úniku moči kvůli nedostatku času dojít na toaletu a/nebo potřeby močit v noci., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
2014-001013-81: Treatment of Bladder Pain Syndrome with Onabotulinum toxin A |
|
|
| Completed | 2 | 30 | Europe | BOTOX®, 9060X, Powder for solution for injection, BOTOX® | Centro Hospitalar de São João, EPE, Centro Hospitalar de São João, EPE | Bladder Pain Syndrome, Bladder Pain Syndrome, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] | | | | |
NCT01969773: Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment |
|
|
| Completed | 2 | 60 | RoW | Botulinum toxin A, BoNT-A, BOTOX, Normal saline instillation, N/S | Buddhist Tzu Chi General Hospital | Interstitial Cystitis | 12/14 | 12/14 | | |
NCT01177358: Botox in the Healing of Surgical Wounds of the Neck |
|
|
| Completed | 2 | 40 | Canada | Botulinum Toxin Type A, Allergan Botox, Drug Identification Number 01981501, Normal Saline | Nova Scotia Health Authority, Allergan | Scar | 05/16 | 05/16 | | |
NCT01678053: Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas |
|
|
| Withdrawn | 2 | 0 | US | onabotulinumtoxinA, BOTOX, Botulinum toxin A, omeprazole (proton pump inhibitor), omeprazole | Phillip Song, MD | Contact Ulcer of Vocal Folds, Granuloma of Vocal Cords, Granuloma, Laryngeal, Granuloma | 01/15 | 01/15 | | |
2010-022255-37: Etude de l’efficacité et de la tolérance, de l’injection intra prostatique de toxine botulique A, chez l’homme, dans le traitement de l’hyperplasie bénigne de prostate symptomatique. |
|
|
| Completed | 2 | 226 | Europe | Powder for solution for injection, Capsule*, Capsule, soft, Film-coated tablet, Tablet, BOTOX 200 Unités ALLERGAN, poudre pour solution injectable, PERMIXON, TADENAN, CHIBRO-PROSCAR, AVODART, MECIR, XATRAL, ZOXAN | CHU de Bordeaux | HBP symptomatique modérée à sévère selon le score IPSS | | | | |
NCT00262496: Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. |
|
|
| Withdrawn | 2 | 0 | US | Botox | US Department of Veterans Affairs | Overactive Bladder, Urinary Incontinence | | | | |
NCT01589471: The Value of Botox-A for Management of Low Anterior Resection Syndrome |
|
|
| Completed | 2 | 23 | Canada | intra-rectal Botulinum toxin A injection, Botox (Allergan) | Centre hospitalier de l'Université de Montréal (CHUM), Allergan | Low Anterior Resection Syndrome, Rectal Cancer | 10/15 | 11/15 | | |
2009-015125-36: Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie |
|
|
| Completed | 2 | 15 | Europe | Vistabel, Vistabel | Medical School Hannover. Department of Psychiatry, Social Psychiatry and Psychotherapy | Botulinum Toxin for the Treatment of Depression | | 12/11 | | |
2005-004834-42: A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study ofPulmonary Function in Patients with Reduced Lung Function Treated with BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex for Focal Upper LimbSpasticity Due to Upper Motor Neuron Syndrome |
|
|
| Completed | 2 | 25 | Europe | Botox, BOTOX, BOTOX | Allergan | Focal upper limb spasticity due to upper motor neuron syndromeincluding poststroke spasticity. (for the objective of this study patients must also have stable compromised baseline respiratory status) | | 08/09 | | |
2008-001158-42: Proof-of-concept study: Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) bei der Behandlung von Krähenfüßen im Vergleich zu Vistabel® im intraindividuellen Vergleich |
|
|
| Completed | 2 | 20 | Europe | Xeomin, Vistabel, Xeomin, Vistabel | Dermatologikum Hamburg | Moderate to severe crow, s feet | | 01/09 | | |
2010-020359-30: Etude pilote prospective multicentrique évaluant l’effet antalgique d’une injection de toxine botulique type A au niveau du ganglion Impar chez des patients présentant des proctalgies chroniques au sens des critères de Rome III |
|
|
| Ongoing | 2 | 18 | Europe | Powder for solution for injection, Botox 100U | CHU de nantes | patients présentant des proctalgies chroniques au sens des critères de Rome III | | | | |
2009-017378-19: Estudio prospectivo controlado sobre el efecto protector de la toxina botulínica tipo a en la sialoadenitis radioinducida |
|
|
| | 2 | 135 | Europe | BOTOX 100 unidades polvo para solución inyectable, BOTOX 100 unidades polvo para solución inyectable | Dr. Antonio Mari Roig | Con este estudio se pretende valorar el posible efecto de radioprotección glandular de la inyección de toxina botulínica previa al inicio del tratamiento con radioterapia debido a la disminución en número de gránulos de secreción, responsables del daño glandular radioinducido. | | | | |
2014-001959-24: Botox for the treatment of facial pain, provoked by an extremely painful irritation of the fifth cranial nerve Botox zur Behandlung des Gesichtsschmerzes, der durch einen äußerst schmerzhaften Reizungszustand des fünften Hirnnerven ausgelöst wird |
|
|
| Ongoing | 2 | 20 | Europe | BOTOX®, Powder for solution for injection, BOTOX® | University Hospital Essen, Allergan Pharmaceuticals Ireland | Trigeminal neuralgia Trigeminusneuralgie, Extremely painful irritation of the fifth cranial nerve accompanied by recurrent and suddenly occurring, eletrifying exacerbation of pain äußerst schmerzhafter Reizungszustand des fünften Hirnnerven, der mit wiederkehrenden, plötzlich einschießenden, elektrisierenden Schmerzattacken über wenige Sekunden einhergeht, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT02044302: A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction |
|
|
| Terminated | 2 | 2 | US | Bupivacaine, Exparel, Marcaine, Sensorcaine, Botulinum Toxins, Botox, Analgesics, narcotic, morphine, sedative, valium | Yale University | Post-operative Pain | 01/16 | 01/16 | | |
NCT02070302: BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome |
|
|
| Completed | 2 | 10 | US | Botulinum Toxin Type A, Botox, Placebo, Normal Saline | Benjamin Sucher, Allergan | Carpal Tunnel Syndrome | 02/16 | 02/16 | | |
| Completed | 2 | 176 | US, Europe, RoW | onabotulinumtoxinA, botulinum toxin Type A, BOTOX®, Normal Saline | Allergan | Osteoarthritis | 03/16 | 03/16 | | |
| Completed | 2 | 7 | Europe | Botox, Botulinum toxin | St. Olavs Hospital, Norwegian University of Science and Technology | Stomach Neoplasms | 05/16 | 05/16 | | |
NCT01309802: A Two-Part Study of BOTOX® Therapy for Ischemic Digits |
|
|
| Completed | 2 | 48 | US | onabotulinum toxin type-A, BOTOX®, botulinum toxin type A | Southern Illinois University | Raynaud's Disease | 05/16 | 07/16 | | |
NCT02116361: OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females |
|
|
| Completed | 2 | 258 | US | onabotulinumtoxinA, BOTOX®, botulinum toxin Type A, Normal Saline | Allergan | Depressive Disorder, Major | 08/16 | 12/16 | | |
NCT02867787: Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin |
|
|
| Unknown status | 2 | 40 | Europe | Botox arm | Versailles Hospital | Tendinopathy Rotator Cuff | 09/16 | 09/16 | | |
NCT01920945: OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study |
|
|
| Terminated | 2 | 6 | US | OnabotulinumtoxinA, Botox | St. Luke's-Roosevelt Hospital Center, Allergan | New Daily Persistent Headache | 10/16 | 10/16 | | |
NCT02735499: Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB) |
|
|
| Completed | 2 | 14 | Europe | onabotulinum toxin A, Botox | The Hospital of Vestfold, South-Eastern Norway Regional Health Authority | Overactive Bladder | 10/16 | 10/16 | | |
NCT02058836: Botulinum Toxin for the Management of Chronic Orchialgia |
|
|
| Completed | 2 | 8 | US | Botox Injection, Botox, Botulinum toxin-A, Normal saline injection, 0.9% Sodium Chloride injection, Saline injection | Wake Forest University Health Sciences, Allergan | Chronic Testicular Pain | 10/16 | 10/16 | | |
NCT02135341: Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility |
|
|
| Completed | 2 | 60 | RoW | Botulinum toxin A, BoNT-A, BOTOX (Allergan, Irvine, CA, USA) | Buddhist Tzu Chi General Hospital | Botulinum Toxins, Type A | 12/16 | 12/16 | | |
| Completed | 2 | 64 | RoW | Xeomin, IncobotulinumtoxinA, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, Botox®, OnabotulinumtoxinA | Merz Pharmaceuticals GmbH, LLC Merz Pharma, Russia | Cerebral Palsy, Spastic Paraplegia and Hemiparesis, Equine and Equinovarus Foot Deformation | 12/16 | 12/16 | | |
NCT02247557: Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis |
|
|
| Completed | 2 | 90 | RoW | Liposome encapsulated BoNT-A, Liposome, onabotulinumtoxinA 200U, BOTOX 200U in normal saline, Normal saline, Saline | Buddhist Tzu Chi General Hospital | Interstitial Cystitis | 02/17 | 02/17 | | |
2015-001402-34: Efficacité et sécurité des injections intramusculaires de toxine botulinique précoces dans la prévention de la déformation de l’épaule des nourrissons atteints de paralysie obstétricale du plexus brachial: un essai multicentrique contrôlé randomisé en double aveugle contre placebo |
|
|
| Ongoing | 2 | 62 | Europe | Toxine Botulique, Solution for injection, BOTOX | CHRU de Brest, CHRU de Brest | La Paralysie Obstétricale du Plexus Brachial (parésie d’un ou des membre(s) supérieur(s)), Parésie d’un ou des membre(s) supérieur(s)), Not possible to specify | | | | |
| Completed | 2 | 12 | US | 100 units of Botulinum Toxin Type A, BOTOX®, Preservative free normal saline, 100 units Botulinum Toxin A, Cross-over | Mohit Khera, Allergan | Peyronie's Disease | 02/17 | 01/19 | | |
NCT02010775: Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy |
|
|
| Completed | 2 | 187 | Canada, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA, Normal saline | Allergan | Masseter Muscle Hypertrophy | 03/17 | 11/17 | | |
2005-001095-13: Intragastrale Injektion von Botulinum Toxin A zur Behandlung der Adipositas |
|
|
| Completed | 2 | 20 | Europe | Botox, Injection*, Botox | Medical University Innsbruck | Die morbide Adipositas nimmt in westlichen Ländern stetig zu. In Österreich und Deutschland sind ca. 30% der Erwachsenen übergewichtig und 1% (900.000 Erwachsene) morbid adipös. In den USA stellt die Adiposita ein schwerwiegendes gesundheitliches Problem dar. Geschätzte 60% der Amerikaner sind übergewichtig und über 6% (12 Millionen) morbid adipös. | | | | |
| Withdrawn | 2 | 0 | US | onabotulinum toxin type-A, Botulinum Toxin Type A, Botox, placebo, 2nd phase - onabotulinum toxin type-A | Southern Illinois University | Neuroma | 05/17 | 09/17 | | |
NCT03076762: Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis |
|
|
| Unknown status | 2 | 60 | RoW | intravesical onabotulinumtoxinA injection, BOTOX | Buddhist Tzu Chi General Hospital | Bladder Pain Syndrome | 08/17 | 08/17 | | |
| Terminated | 2 | 59 | US, Europe | OnabotulinumtoxinA, BOTOX®, Botulinum Toxin Type A, Normal Saline | Allergan | Premature Ejaculation | 08/17 | 08/17 | | |
2017-002866-38: Study to evaluate the efficacy of OnabotulinumtoxinA in migraine Studio per valutare l'efficacia della tossina botulinica A nell'emicrania |
|
|
| Ongoing | 2 | 42 | Europe | tossina botulinica A, M03AX01, Powder for solution for injection, BOTOX - 100 UNIT ALLERGAN POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO | IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO, Allergan | Migraine Emicrania, Migraine Emicrania, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 2 | 15 | US | Hyper-Diluted Botox, Topical anesthesia, 0.9% saline solution | Steve Yoelin M.D. Medical Associates, Inc., Allergan | Skin Quality | 07/18 | 07/18 | | |
NCT02736890: Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury |
|
|
| Terminated | 2 | 8 | US | Botulinum Toxin A, Botox, Placebo | Icahn School of Medicine at Mount Sinai | Neuropathic Back Pain, Spinal Cord Injury | 07/18 | 07/18 | | |
| Completed | 2 | 11 | Europe | botox injection Multiguide, Botulinum toxin type A | Norwegian University of Science and Technology, St. Olavs Hospital | Chronic Disease, Nasal Polyposis, Rhinitis | 09/18 | 12/18 | | |
| Withdrawn | 2 | 0 | US | Botulinum toxin, Corticosteroid injection into Carpal Tunnel | University of Minnesota | Carpal Tunnel Syndrome | 10/18 | 10/18 | | |
| Completed | 2 | 64 | Canada | Botox, OnabotulinumtoxinA, Placebo | Mount Sinai Hospital, Canada | Scrotal Pain | 10/18 | 10/18 | | |
NCT03055767: Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population |
|
|
| Completed | 2 | 17 | US | OnabotulinumtoxinA, Botox, Placebo (Saline) | University of California, Irvine, American Society of Regional Anesthesia | Migraine Disorders, Headache, Migraine, Pediatrics | 11/18 | 04/20 | | |
NCT02623829: Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study) |
|
|
| Completed | 2 | 42 | US | Botulinum Toxin, Botox,, OnabotulinumtoxinA, Saline, placebo | Icahn School of Medicine at Mount Sinai, Allergan | Post-operative Excessive Scarring | 03/19 | 03/19 | | |
BTX-BPD, NCT02728778: Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) |
|
|
| Completed | 2 | 54 | Europe | incobotulinumtoxin A, Botox, Acupuncture | Hannover Medical School | Borderline Personality Disorder | 04/19 | 10/19 | | |
NCT03631368: Treatment of Hypertrophic Scars With Intradermal Botox |
|
|
| Unknown status | 2 | 20 | US | Botox | Roy G. Geronemus, M.D., Allergan | Hypertrophic Scar | 05/19 | 05/19 | | |
NCT02160288: Effects of Botox in Obstructed Defecation Syndrome |
|
|
| Terminated | 2 | 1 | US | Botulinum Toxin-A, Botox, Normal Saline, 0.9% Sodium Chloride | Massachusetts General Hospital | Obstructed Defecation Syndrome (ODS) | 06/19 | 06/19 | | |
NCT03301272: Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease |
|
|
| Completed | 2 | 16 | US | Onabotulinumtoxin A Injection, Botox, Placebo, Normal saline | University of North Carolina, Chapel Hill | Parkinson Disease | 08/19 | 08/19 | | |
2018-004239-63: BOTOX® to prevent post-operative pancreatic fistals after pancreatic surgery. PROFITstudy. |
|
|
| Not yet recruiting | 2 | 50 | Europe | BOTOX® (Allergan), RVG 117147, Powder for solution for injection, BOTOX® (Allergan) | Erasmus MC, Erasmus MC | Post-operative pancreatic fistula, Post-operative pancreatic fistula, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT01589263: Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS |
|
|
| Completed | 2 | 63 | US | onaBoNT-A + placebo, Botox, Tamsulosin + placebo, Flomax | VA Office of Research and Development | Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms | 09/19 | 09/19 | | |
| Unknown status | 2 | 588 | Europe | Botox (onabotulinumtoxinA), NeuroBloc/Myobloc (rimabotulinumtoxinB), NaCl (placebo) | Carl Swartling | Hyperhidrosis | 10/19 | 10/19 | | |
ACTRN12620000067976: Botox injection into the pelvic floor muscles for the treatment of chronic pelvic pain. |
|
|
| Completed | 2 | 20 | | | Mercy Hospital, Norman Beischer Medical Research Foundation | chronic pelvic pain | | | | |
ChemoCast, NCT03903653: Botulinum Toxin A & Weekly Serial Casting in ABI Inpatients With Lower Extremity Spasticity |
|
|
| Withdrawn | 2 | 20 | NA | Botulinum toxin type A, Botox, Serial Casting, Casting | Hamilton Health Sciences Corporation | Spastic Foot | 11/19 | 12/19 | | |
NCT03827122: Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study |
|
|
| Unknown status | 2 | 20 | RoW | onabotulinumtoxinA, Botox Allergan | Riyadh Colleges of Dentistry and Pharmacy | Nocturnal Bruxism | 11/19 | 11/19 | | |
2018-004696-12: Evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis Valutazione dell'uso combinato della Tossina Botulinica e dell’Acido Ialuronico nel trattamento della paralisi facciale |
|
|
| Not yet recruiting | 2 | 70 | Europe | VISTABEX, [TOSSINA BOTULINICA DI TIPO A], Powder for solution for injection, VISTABEX - 4 UNITA'/0.1 ML POLVERE PER SOLUZIONE INIETTABILE FLACONCINO DA 50 UNITA' | AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA, AOUI Verona, ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED | hemifacial paralysis (3 to 6 of the House-Brackmann scale) paralisi emifacciale da 3 a 6 della scala House-Brackmann, hemifacial paralysis paralisi emifacciale, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT03915067: BOTOX® for the Treatment of Platysma Prominence |
|
|
| Completed | 2 | 171 | Canada, US | BOTOX® purified neurotoxin complex, Botulinum toxin type A purified neurotoxin complex, Placebo | Allergan | Platysma Prominence | 04/20 | 04/20 | | |
2019-004704-35: Jaw muscle pain relief following local injection with Botox. A randomized double-blind controlled multicenter pilot study |
|
|
| Completed | 2 | 48 | Europe | Powder for solution for injection, Botox 100 Allergan-units | Region Örebro, Region Örebro, Centrum för specialisttandvård, Region Västmanland, Hälso- och sjukvårdsförvaltningen | Myalgia of jaw muscle, Jaw muscle pain, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Completed | 2 | 32 | Europe | OnabotulinumtoxinA, BonT-A (Botox®) | IRCCS National Neurological Institute "C. Mondino" Foundation | Migraine | 05/20 | 05/20 | | |
APOLLO, NCT03320850: BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence |
|
|
| Completed | 2 | 383 | Canada, US | OnabotulinumtoxinA and Hydrogel admixture, BOTOX®, Botulinum Toxin Type A, Placebo and Hydrogel admixture | Allergan | Urinary Incontinence, Overactive Bladder With Urinary Incontinence | 07/20 | 07/20 | | |
| Completed | 2 | 208 | Europe, Canada, US | Botulinum toxin A "BoNT/A-DP", Botulinum toxin A "Botox Cosmetics" | Croma-Pharma GmbH, Hugel | Frown Lines | 11/20 | 02/21 | | |
NCT02662530: Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia |
|
|
| Unknown status | 2 | 39 | Canada | Botulinum Toxin Type A, Botox, onabotulinumtoxinA | Western University, Canada | Cervical Dystonia | 12/20 | 01/21 | | |
NCT04426123: Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A. |
|
|
| Unknown status | 2 | 48 | NA | Botulinum toxin type A, Botox, saline solution, Physiologic NaCl | Region Örebro County, Region Västmanland, Landstinget i Värmland | Myalgia, Myofascial Pain | 12/20 | 12/21 | | |
| Completed | 2 | 20 | Europe | BoNT-A, Botox, Botulinum Toxin Type A | Norwegian University of Science and Technology, St. Olavs Hospital, Mayo Clinic | Migraine Disorders, Chronic Disease | 01/21 | 01/21 | | |
